Trial Profile

Blood Detection of EGFR Mutation For Iressa Treatment

Status: Active, no longer recruiting

Phase of Trial: Phase II

Latest Information Update: 08 Aug 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Gefitinib (Primary)
Indications Adenocarcinoma; Lung cancer; Non-small cell lung cancer
Focus Therapeutic Use
Acronyms BENEFIT

Most Recent Events

10 Sep 2019 Results assessing the underlying mechanisms that potentially affect prognosis to EGFR-TKI in EGFR-positive patients with non-small cell lung cancer presented at the 20th World Conference on Lung Cancer
18 Oct 2017 Results (n=152; data cut off: January 31, 2017) assessing efficacy presented at the 18th World Conference on Lung Cancer.
22 Feb 2017 Planned End Date changed from 1 Feb 2017 to 1 Feb 2018.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com